SGMT•benzinga•
Sagimet Biosciences Reported Denifanstat Met All Primary And Secondary Endpoints In A Phase 3 Clinical Trial For The Treatment Of Moderate To Severe Acne Vulgaris Conducted By Sagimet's License Partner Ascletis Bioscience Co. Ltd. (Ascletis) In China
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 4, 2025 by benzinga